gefitinib,osimertinib
astrazeneca
['gefitinib', 'nsclc', 'osimertinib', 'sclc']
the #oncoalerttoptweet day1 of #asco23 tweet by our oncoalert faculty ph iii trial jcog1404 of cis/pem + egfr tki in 1l egfrmt nsclc: - initially designed with gefitinib, study amended to osimertinib during the study - marginal pfs benefit with tki+chemo 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨